EU Compassionate Use Programmes (CUPs)

@article{Sou2012EUCU,
  title={EU Compassionate Use Programmes (CUPs)},
  author={H{\'e}l{\`e}ne Sou},
  journal={Pharmaceutical Medicine},
  year={2012},
  volume={24},
  pages={223-229}
}
  • Hélène Sou
  • Published 1 August 2010
  • Medicine
  • Pharmaceutical Medicine
For some patients, compassionate use programmes (CUPs) are the only way to access promising medicinal products that are not yet authorized and for which clinical trials are either not available or in which these patients cannot participate. For such patients, the CUP benefits can be very important. Although an EU regulatory framework exists, there is no single, centralized EU-wide procedure for CUPs. Each Member State has its own procedures and CUP approvals are governed by national regulatory… 

The Evolving Landscape of Early Access Programmes: Comparisons and Implications for Market Access.

Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France

NPPs should be harmonised throughout Europe in order to ensure equal availability of treatment and therapeutic benefit to all Europeans without compromising patient safety, and provide a unique opportunity to study both the benefits and risks of unregistered products for treating rare diseases.

Global Access Programs: A Collaborative Approach for Effective Implementation and Management

The triggers for early access requests are considered and the need for companies to develop a global strategy for GAPs in order to respond appropriately to requests forEarly access is examined, along with the considerations affecting the type and scope of GAP.

Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.

A REVIEW ON CLINICAL TRIALS: WHY TO INTRODUCE ZERO PHASE

It is concluded that Phase “0” in clinical trials can work as a useful parameter to measure drug safety at subtherapeutic level and the fundamental requirements of clinical studies conducted under an exploratory IND are reviewed and some common misconceptions regarding phase 0 trials are addressed.

Compassionate Use Cases Treated with Hemoglobin-Based Oxygen Carriers

One of the most elusive goals in the modern medical era has been to design a safe and effective asanquinous oxygen therapeutic (OT) - most of the 17 billion people in the world are still without an alternative to blood.